Get started
Work

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Year: 2022
Type: article
Study design: Observational Study
Source: Blood
DOI: 10.1182/blood-2022-168349
Authors: Mithun V. Shah, Christopher N Hahn, Rakchha Chhetri, Elizabeth Ngoc Hoa Tran, Deepak Singhal, William J. Hogan, Monika M Kutyna, Hassan B. Alkhateeb, Aref Al-Kali, Naseema Gangat, Mark R. Litzow, Begna Kebede, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Ayalew Tefferi, Anmol Baranwal, Naranie Shanmuganathan, Sharad Kumar, Daniel Thomas, Chung Hoow Kok, Devendra Hiwase
Institutions: Mayo Clinic, South Australia Pathology, University of South Australia, Centre for Cancer Biology, Royal Adelaide Hospital, South Australian Health and Medical Research Institute, The University of Adelaide
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4310096992
FWCI:
Cites:
Cited by:
Related to: 10